羟氯喹和伊维菌素治疗住院 COVID-19 患者的结局：单中心经验。

Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience.

机构信息

Hospital Samaritano - Botafogo (RJ), Brazil.

Universidade Federal do Rio de Janeiro, Instituto do Coração Edson Saad - Rio de Janeiro (RJ), Brazil.

出版信息

Rev Assoc Med Bras (1992). 2021 Oct;67(10):1466-1471. doi: 10.1590/1806-9282.20210661.

DOI:10.1590/1806-9282.20210661

PMID:35018977

Abstract

OBJECTIVE

Hydroxychloroquine and Ivermectin are advocated as potential treatments for coronavirus disease 2019 (COVID-19) despite the lack of supportive clinical evidence. In this study, outcomes associated with Hydroxychloroquine and/or Ivermectin were determined in a series of patients with confirmed COVID-19 from a single institution in Brazil.

METHODS

Consecutive patients admitted between March and July 2020 were retrospectively analyzed and divided into four treatment categories: no treatment (Group 0), Ivermectin only (Group I), Hydroxychloroquine only (Group II), and Hydroxychloroquine and Ivermectin (Group III). Intensive care unit admission, mechanical ventilation, and death were compared between the Groups.

RESULTS

A total of 230 patients were included, with the following treatment distribution: 35.2% (0), 9.1% (I), 48.3% (II), and 7.4% (III). Groups I, II, and III had the higher rates of Intensive care unit admission, mechanical ventilation, or death (0: 23.5% versus I: 38.1% versus II: 37.8% versus III: 70.6%, p=0.002), and the greatest mortality was found in Group III (0 versus III: 13.6% versus 35.3%, p=0.03). In the multivariate analysis, Hydroxychloroquine remained significantly associated with death (OR 3.3, 95%CI 1.1-9.6, p=0.03).

CONCLUSION

In a series of consecutive hospitalized patients with COVID-19, Ivermectin was not associated with improved outcomes and Hydroxychloroquine may have resulted in a harmful effect.

摘要

目的

羟氯喹和伊维菌素被提倡作为治疗 2019 年冠状病毒病（COVID-19）的潜在药物，尽管缺乏支持的临床证据。在这项研究中，对来自巴西一家机构的一系列确诊 COVID-19 患者中使用羟氯喹和/或伊维菌素的结果进行了确定。

方法

回顾性分析了 2020 年 3 月至 7 月间连续入院的患者，并将其分为四组治疗类别：未治疗（第 0 组）、仅用伊维菌素（第 I 组）、仅用羟氯喹（第 II 组）和羟氯喹和伊维菌素（第 III 组）。比较各组之间的重症监护病房（ICU）入院、机械通气和死亡情况。

结果

共纳入 230 例患者，其治疗分布如下：35.2%（第 0 组）、9.1%（第 I 组）、48.3%（第 II 组）和 7.4%（第 III 组）。第 I、II 和 III 组 ICU 入院、机械通气或死亡的发生率更高（第 0 组：23.5%，第 I 组：38.1%，第 II 组：37.8%，第 III 组：70.6%，p=0.002），第 III 组死亡率最高（第 0 组：13.6%，第 III 组：35.3%，p=0.03）。多变量分析显示，羟氯喹与死亡显著相关（OR 3.3，95%CI 1.1-9.6，p=0.03）。